New estimates reveal Phelan-McDermid syndrome (PMS), a rare genetic disorder linked to autism spectrum disorder (ASD), is significantly more prevalent than formerly believed. A multidisciplinary study led by researchers at the Seaver Autism Center, Icahn School of Medicine at Mount Sinai, analyzed genetic data from nearly 180,000 individuals with autism to refine the prevalence of PMS. Their findings, recently published in Autism Research, suggest that PMS affects approximately 1 in 7,300 individuals—dramatically higher than previous estimates.
Phelan-McDermid syndrome arises from deletions or mutations of the SHANK3 gene on chromosome 22, a gene critically involved in synaptic function and neurodevelopment. These genetic alterations impair neural connectivity and contribute to a spectrum of symptoms, including intellectual disabilities, developmental delays, and a high incidence of ASD traits. Up to 1% of ASD cases are linked to SHANK3 abnormalities, positioning PMS as a crucial subtype within autism genetics.
The research team integrated data across multiple sources, including genetic testing laboratories and autism research consortia. By compiling data sets from GeneDx, LabCorp, Ambry Genetics, the SPARK study, and the Autism Sequencing Consortium, they created a comprehensive prevalence model. This multisource approach allowed them to adjust for undiagnosed individuals, limitations in current genetic testing methodologies, and those with PMS who do not meet ASD criteria, leading to more accurate population estimates.
One striking implication of the study is the recognition of underutilization of genetic testing among individuals with developmental disabilities and autism. Barriers such as insurance restrictions and insufficient gene coverage in common panels contribute to a large number of undiagnosed cases. As a result, tens of thousands of Americans likely live with PMS without a formal genetic diagnosis.
Experts emphasize that genetic diagnosis is pivotal as therapeutic strategies begin to emerge. Advances in precision medicine target the molecular mechanisms underlying PMS, and clinical trials investigating these approaches are actively ongoing. Precision diagnostics will enable more effective patient stratification and accelerate the development of disease-modifying treatments.
The study arrives at a critical juncture, underscoring the necessity for broader access to comprehensive genetic testing in neurodevelopmental disorders. Identifying individuals with PMS not only facilitates personalized clinical care and informs family counseling, but also expands participation in research and clinical trials. Consequently, the findings bolster advocacy efforts to promote genetic screening as a frontline diagnostic tool for autism spectrum disorders.
In summary, this landmark research enhances understanding of PMS’s true impact and calls for systemic improvements in genetic testing practices. As innovative therapies advance, ensuring accurate and timely diagnosis will be essential to translating molecular discoveries into meaningful clinical benefits for affected individuals and families.
Subject of Research: People
Article Title: Prevalence of Phelan McDermid Syndrome Estimated To Be ~1:7300 Using a Multisource Model
News Publication Date: July 9, 2026
Web References: https://onlinelibrary.wiley.com/doi/10.1002/aur.70297
References: 10.1002/aur.70297
Keywords: Phelan-McDermid syndrome, SHANK3, autism spectrum disorder, genetic testing, neurodevelopmental disorders, precision medicine, prevalence
